300 related articles for article (PubMed ID: 29039822)
1. Ribociclib (Kisqali) for advanced or metastatic breast cancer.
Med Lett Drugs Ther; 2017 Oct; 59(1532):e178-e179. PubMed ID: 29039822
[No Abstract] [Full Text] [Related]
2. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
[No Abstract] [Full Text] [Related]
3. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
4. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP; Ricci F; Loirat D; Jobard A; Basse C; Romano E; Le Tourneau C; Dieras V
Bull Cancer; 2017 Feb; 104(2):114-122. PubMed ID: 28126188
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
6. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
7. Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Echavarria I; Martin M
Future Oncol; 2017 Oct; 13(24):2137-2149. PubMed ID: 28758424
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer.
Micha JP; Rettenmaier MA; Bohart RD; Goldstein BH
J Oncol Pharm Pract; 2024 Apr; 30(3):547-551. PubMed ID: 38404005
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib in HR-positive, HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
[No Abstract] [Full Text] [Related]
10. Clinical development of CDK4/6 inhibitor for breast cancer.
Iwata H
Breast Cancer; 2018 Jul; 25(4):402-406. PubMed ID: 29392622
[TBL] [Abstract][Full Text] [Related]
11. A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.
Guerini AE; Pedretti S; Salah E; Simoncini EL; Maddalo M; Pegurri L; Pedersini R; Vassalli L; Pasinetti N; Peretto G; Triggiani L; Costantino G; Figlia V; Alongi F; Magrini SM; Buglione M
Sci Rep; 2020 Aug; 10(1):13589. PubMed ID: 32788596
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
Shah M; Nunes MR; Stearns V
Oncology (Williston Park); 2018 May; 32(5):216-22. PubMed ID: 29847850
[TBL] [Abstract][Full Text] [Related]
14. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data.
Vidula N; Rugo HS
Clin Breast Cancer; 2016 Feb; 16(1):8-17. PubMed ID: 26303211
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
17. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
18. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
19. Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Weiss J; Afghahi A; Shagisultanova E; Diamond JR
Oncology (Williston Park); 2018 Oct; 32(10):513-5. PubMed ID: 30334242
[No Abstract] [Full Text] [Related]
20. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Bautista F; Paoletti X; Rubino J; Brard C; Rezai K; Nebchi S; Andre N; Aerts I; De Carli E; van Eijkelenburg N; Thebaud E; Corradini N; Defachelles AS; Ducassou S; Morscher RJ; Vassal G; Geoerger B
J Clin Oncol; 2021 Nov; 39(32):3546-3560. PubMed ID: 34347542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]